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The immune system of the gut has evolved a number of specific lymphoid structures that 
contribute to homeostasis in the face of microbial colonization and food-derived anti-
genic challenge. These lymphoid organs encompass Peyer’s patches (PP) in the small 
intestine and their colonic counterparts that develop in a programed fashion before birth. 
In addition, the gut harbors a network of lymphoid tissues that is commonly designated 
as solitary intestinal lymphoid tissues (SILT). In contrast to PP, SILT develop strictly after 
birth and consist of a dynamic continuum of structures ranging from small cryptopatches 
(CP) to large, mature isolated lymphoid follicles (ILF). Although the development of PP 
and SILT follow similar principles, such as an early clustering of lymphoid tissue inducer 
(LTi) cells and the requirement for lymphotoxin beta (LTβ) receptor-mediated signaling, 
the formation of CP and their further maturation into ILF is associated with additional 
intrinsic and environmental signals. Moreover, recent data also indicate that specific 
differences exist in the regulation of ILF formation between the small intestine and the 
colon. Importantly, intestinal inflammation in both mice and humans is associated with 
a strong expansion of the lymphoid network in the gut. Recent experiments in mice 
suggest that these structures, although they resemble large, mature ILF in appearance, 
may represent de novo-induced tertiary lymphoid organs (TLO). While, so far, it is not 
clear whether intestinal TLO contribute to the exacerbation of inflammatory pathology, 
it has been shown that ILF provide the critical microenvironment necessary for the 
induction of an effective host response upon infection with enteric bacterial pathogens. 
Regarding the importance of ILF for intestinal immunity, interfering with the development 
and maturation of these lymphoid tissues may offer novel means for manipulating the 
immune response during intestinal infection or inflammation.
Keywords: isolated lymphoid follicles, cryptopatch, lymphoid tissue inducer cells, tertiary lymphoid organs, small 
intestine, large intestine
Abbreviations: CP, cryptopatches; ILC, innate lymphoid cells; ILF, isolated lymphoid follicles; LTi, lymphoid tissue inducer; 
LTo, lymphoid tissue organizer; PP, Peyer’s patches; SILT, solitary intestinal lymphoid tissues; SLO, secondary lymphoid organs; 
TLO, tertiary lymphoid organs.
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iNTRODUCTiON
Lymphatic organs were described very early in history. The first 
description of the spleen was made in Egypt 3000 years B.C., 
and the mesenteric lymph node was mentioned by Herophilus 
in 335–280 B.C. (1, 2). The thymus was characterized in the 
fifteenth century, but the immunological function of these 
organs was recognized not until the twentieth century (2,  3). 
The thymus and bone marrow are referred to as primary 
lymphatic organs and represent the places in the body where 
T and B lymphocytes development and selection takes place. 
Secondary lymphatic organs (SLO), such as the spleen and 
lymph nodes (LN), develop at predetermined locations during 
embryonic development and provide the microenvironment 
that is required for lymphocyte activation and differentiation 
into regulatory or effector cells. The strategic positioning of SLO 
allows optimal sampling of self- and non-self-derived antigens 
that reach the SLO via the bloodstream (spleen) or the affer-
ent lymphatics, which also transport antigen-presenting cells 
from tissues toward the SLO. In addition to the programed 
development of SLO, it is now well appreciated that structured 
lymphoid organs can also develop after birth in response to an 
ongoing immune reaction. These organized lymphoid aggregates 
resemble SLO and are designated as tertiary lymphoid organs 
(TLO) or ectopic lymphoid tissues. Formation of TLO has been 
observed in almost every tissue of the body under inflammatory 
conditions associated with autoimmunity, infection, or cancer 
[summarized in Pitzalis et al. (4)].
The mucosal surfaces of the body represent a major entry 
site for non-self antigens. It is, thus, not surprising that these 
barrier sites are surveyed by specific SLO that can be differenti-
ated according to their location as nasal-associated lymphoid 
tissues (NALT), bronchus-associated lymphoid tissues (BALT), 
or gut-associated lymphoid tissues (GALT). It is, in particular, 
the intestine that has evolved a range of unique lymphoid organs, 
reflecting the extraordinary challenge for the intestinal immune 
system of maintaining tolerance to food antigens and the complex 
commensal microbiota, while at the same time preserving tissue 
integrity and the ability to fight harmful pathogens. In this review, 
we will focus on the different types of intestinal lymphoid organs, 
their development, and function in intestinal inflammation 
and infection. We will, furthermore, point out similarities and 
specific differences regarding the development and maturation 
of lymphoid tissues between the small intestine and the colon. 
A special focus will be set on isolated lymphoid follicles (ILF), 
which show features of TLO such as the postnatal development 
and the requirement for additional activating signals to promote 
their formation.
PROGRAMeD SLO DeveLOPMeNT 
iN THe GUT
The principal molecular mechanisms that govern the develop-
ment of SLO have been extensively characterized during the 
past two decades (5, 6), and various cell types and factors were 
identified to be crucial for their development. In the gut, a chain 
of several LN embedded in the mesenteric membranes drain 
antigens from the intestine. Despite their common location, the 
mesenteric (m)LN that drain the small intestine and colon in 
mice can be separated anatomically and by distinct specificities 
in their immunological functions (7). The development of mLN 
follows the general molecular processes described for LN for-
mation, which we will first summarize here, before pointing out 
major similarities and differences to the development of another 
major SLO in the gut, the Peyer’s patches (PP).
Similar to all other LN, mLN formation starts during embryo-
genesis in utero and proceeds until the development is completely 
finished after birth. The mLN are the first LN to develop in the 
mouse, probably starting already around embryonic day (E) 
9–12.5 (8). Nerve fibers were identified as potential producers 
of retinaldehyde dehydrogenase 2 (RALDH2) (5, 9), an enzyme 
that converts retinal into retinoic acid (RA). RA induces the 
production of the chemokine CXCL13 by mesenchymal cells in 
the LN primordium (also designated as LN anlagen). The origin 
of these mesenchymal cells is not completely clear, but adipocyte 
progenitor cells were shown to differentiate into LN stromal cells 
via lymphotoxin beta receptor (LTβR) signaling and upregulation 
of CXCL13 (10). At E13, mesenchymal cells surround endothelial 
cells (EC), which express EC markers such as podoplanin (also 
known as gp38), intercellular adhesion molecule (ICAM)-1, 
and Lyve1+ and produce CCL21 (5, 11). CXCL13 and CCL21 
together attract a population of CD3− CD4+/− CD45+ lymphoid 
tissue inducer (LTi) cells into the developing LN primordium 
(5, 11). LTi cells differentiate from fetal liver cells and have been 
characterized as IL-7Rα+, RA receptor-related orphan receptor 
(ROR)γt+, CXCR5+, CD117+, and RANKL+ (12). It has become 
clear that LTi cells belong to a group of lymphoid cells that is now 
commonly designated as innate lymphoid cells (ILC) (13). LTi 
cells resemble group 3 ILC, due to the shared requirement for 
RORγt expression for their generation and function. Yet, LTi cells 
may form an independent ILC subset, since they were shown to 
develop from a specific LTi precursor aside from all other ILC 
subsets (14, 15). Importantly, LTi cells also express lymphotoxin 
(LT) α1β2 on their surface, which binds to LTβR on gp38+ stromal 
lymphoid tissue organizer (LTo) cells (11). Notably, stromal 
LTo cells express markers found on mesenchymal cells such as 
platelet-derived growth factor receptor (PDGFR) α (11), indicat-
ing that these cells originate from the mesenchymal cells present 
in the LN anlagen. The binding of LTα1β2 and LTβR is essential 
for LN development, as deficiency for LTα, LTβ, or LTβR results 
in the absence of LN (8, 16, 17). Therefore, the initial clustering 
of LTi cells and their interaction with stromal LTo cells marks 
an important step in LN development. Activated LTo cells start 
to express high levels of ICAM-1, VCAM-1, and MAdCAM-1 
(11), which paves the way for further recruitment and retention 
of hematopoietic cells into the developing LN. IL-7 and RANKL 
(also known as TRANCE) produced by LTi and LTo cells were 
both found to be inducers of LTα1β2. Likewise, LTα1β2 signaling 
to LTβR leads to the production of IL-7 and RANKL, resulting 
in a positive feedback loop, and the accumulation of more LTi 
cells to the LN primordium (18). Loss of IL-7 or RANKL was 
shown to result in abnormal LN microarchitecture or even 
complete absence of LN due to altered LTi cell migration or 
high endothelial venule (HEV) formation, respectively (18, 19). 
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The connection of HEV and lymphatic vessels to the LN medi-
ated by LTo cells via VEGF-C production enables lymphocytes 
to colonize the LN and to migrate to their distinct B- and T-cell 
zones (20). LTo cells eventually differentiate into LN stromal cell 
subsets such as fibroblastic reticular cells (FRC) and follicular 
dendritic cells (FDC).
PeYeR’S PATCHeS DeveLOPMeNT
The development of PP starts on E12.5–15.5 (21, 22). Similar to 
LN development, LTi cells play a pivotal role in the formation of 
PP, as in the absence of LTi cells in RORγt- or ID2-deficient mice 
PP fail to develop (23, 24). Recruitment of LTi cells to the PP 
primordium depends on the chemokine CXCL13 and its recep-
tor CXCR5. However, whereas PP were described to be absent 
or strongly reduced in CXCL13- or CXCR5-deficient animals 
(25, 26), mLN were still present, even in mice with a combined 
deficiency in CXCR5 and CCR7, the receptor for CCL19/CCL21 
(26–28). The expression of the adhesion molecule β1 integrin on 
LTi cells directs them to VCAM1+ stromal LTo cells (29), and 
IL-7/RANKL expression by LTo cells leads to an upregulated 
expression of LTα1β2 by LTi cells (30). In contrast to LN develop-
ment, however, both IL-7 and RANKL seem not to be pivotal for 
the development of PP, as PP primordia were detectable in IL-7−/− 
mice at E18 (31) and small PP develop in RANKL−/− mice (32). 
More important in the formation of PP seems to be the IL-7Rα or 
receptor tyrosine kinase Kit expression on LTi cells (19, 21, 31). 
The formation of PP primordia in IL-7Rα−/− mice is disturbed 
and not detectable, and a defect Kit/Kit ligand axis resulted in 
a reduced PP development (19, 21). Importantly, the first cell 
population unique for PP formation and responsible for the clus-
tering of LTi cells in the intestine is of hematopoietic origin. These 
cells were detected to be CD45+, IL7Rα− CD4+, CD3− CD11c+ 
and showed similarities to dendritic cells (DC) from the adult 
spleen (22). These CD11c+ cells express two molecules known 
to be pivotal in PP formation: LTβ and the receptor tyrosine 
kinase RET. Deficiency for one of these molecules resulted in 
complete loss of PP development. Furthermore, RET signaling 
was observed to be dependent on different RET ligands (Artn 
and Nrtn) expressed on VCAM1+ stromal cells. However, the loss 
of one of these ligands only resulted in a reduced number of PP. 
Thus, although similar molecules and signaling pathways govern 
both the formation of PP and LN, there are specific differences in 
the relative requirement for specific cell types and factors during 
their development.
SPeCiAL LYMPHOiD ORGANS OF THe 
SMALL iNTeSTiNe – THe CP/iLF NeTwORK
In addition to the PP, the small intestine harbors a large number of 
organized lymphoid structures that are commonly designated as 
solitary intestinal lymphoid tissues (SILT). In contrast to PP and 
all other secondary lymphoid organs, SILT development in the 
small intestine of mice is initiated during the early postnatal phase 
and starts with the accumulation of RORγt+ IL-7Rα+ LTi cells 
into small clusters named cryptopatches (CP), according to their 
anatomical location at the bottom of intestinal crypts (33,  34). 
While in the first days after birth lymphocytes in the intestine 
are almost exclusively found in the nascent PP (35), CP start to 
recruit lymphocytes during the following weeks and develop into 
ILF. Around 100–200 ILF can be found in the small intestine of a 
mouse, that contain variable numbers of cells and can reach the 
size of a single PP follicle (36). Large, mature ILF contain mainly 
B cells as well as a number of interspersed LTi cells and few CD4+ 
T cells, which do, however, not segregate into a confined T cell 
zone (34, 36). ILF and their CP precursors also contain CD11c+ 
CD11b− DC, which play an important role for the development 
and structural maintenance of ILFs (37). Most of the B cells 
within ILF are conventional B-2 B cells, of which around 10% 
represent IgA+ plasma cells (36). Accordingly, mature ILF have 
been shown to contain germinal centers and serve as inductive 
sites for antigen-specific IgA responses (38). In addition, ILF have 
been proposed to be a major site for T cell-independent B cell 
class switch to IgA (39). Similar to PP, the epithelium adjacent 
to mature ILF shows the characteristics of a follicle-associated 
epithelium containing M cells that allow for direct uptake of 
antigens from the intestinal lumen (36, 40). An overview on the 
structure and cellularity of the different lymphoid organs of the 
small intestine is given in Figure 1.
The development of ILF follows similar molecular principles 
that have been described for the development of PP, such as the 
interaction of LTα1β2 expressed by LTi cells with the LTβR on 
VCAM-1+ stromal LTo cells as a critical requirement for the 
development of CP (40, 41). Transition from CP into ILF in the 
small intestine depends on the secretion of the B cell recruiting 
chemokine CXCL13 by stromal cells and CD11c+ DC within CP/
ILF (37). Consequently, either the deficiency for CXCL13 or its 
receptor CXCR5 results in the absence of ILF, whereas the numbers 
of CP is not affected (37, 42). It should be emphasized here that the 
development of CP, although initiated after birth, proceeds in the 
absence of any exogenous inflammatory stimuli. Furthermore, 
the formation of small intestinal SILT strictly depends on LTi 
cells, as evidenced by the absence of these structures in RORγt-
deficient mice, which lack all LTi cells in the intestine (34, 39). 
Taking this into account, it is, thus, reasonable to consider ILF as 
true SLO. Unlike the development of all other SLO, however, the 
formation of ILF is not completely “programed,” and still requires 
additional input from environmental factors.
Evidence for the requirement of specific dietary products for 
the development of SILT stems from studies showing that mice 
deficient for the Aryl hydrocarbon receptor (Ahr) show an almost 
complete lack of CP/ILF in their small intestines, while the for-
mation of PP or LN was not affected (43, 44). Natural ligands for 
the Ahr include polyphenols and glucosinolates that can be found 
in Brassicaceae plants (such as broccoli or cauliflower). Feeding 
mice with a synthetic diet devoid of any plant-derived products 
resulted in the absence of CP and ILF at 4 weeks after birth, a 
phenotype that could be completely restored by the addition of 
the Ahr ligand indole-3-carbinol to the diet (43). Importantly, 
tissue-specific deletion of Ahr in RORγt+ ILC was sufficient to 
impair the development of CP, further demonstrating the impor-
tance of these cells for CP/ILF induction. Although the exact 
molecular mechanisms remain elusive, it is likely that Ahr does 
not regulate the function, but rather the pool size of RORγt+ ILC 
FiGURe 1 | Overview on the anatomy and structure of CP, iLF, and PP in the small intestine. SILT consists of a dynamic continuum of structures ranging 
from small cryptopatches (CP) to large mature isolated lymphoid follicles (ILF). CP start to develop into immature ILF by recruiting B cells. Mature ILF contain one big 
B cell follicle and develop germinal centers, vascular structures, and a follicle-associated epithelium. PP represent the most structured lymphoid organs in the 
intestine, containing several B cell follicles and distinct T and B cell areas.
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after birth, since ILC-specific loss of Ahr was shown to interfere 
with the postnatal expansion/survival of these cells (43, 44). 
Vitamin A, a dietary component, was also recently found to be 
required for normal numbers of RORγt+ ILC and ILF formation 
(45). Although the different stages of the SILT (CP, immature and 
mature ILF) were present in mice fed with a vitamin A-deficient 
diet, their total numbers were reduced in the middle and distal 
part of the intestine. It is likely that the development of fewer SILT 
in these mice is a consequence of the reduced numbers of RORγt+ 
ILC upon vitamin A deficiency.
Besides this unexpected role of dietary products in the initial 
steps of ILF formation, it is less surprising that the intestinal 
microbiota also plays a role in the regulation of SILT develop-
ment. In this regard, it has been observed that the small intestine 
of germ-free mice contain normal numbers of CP and some 
small immature ILF which harbor only few B cells, whereas the 
transition into mature ILF depends on the presence of a bacte-
rial microbiota (33, 46, 47). A range of receptors and adaptor 
molecules involved in the recognition of bacteria-derived 
molecular patterns, including toll-like receptors (TLR) 2/4, 
myeloid differentiation primary response gene (MyD) 88, and 
nucleotide-binding oligomerization domain-containing protein 
(NOD) 2, were shown to contribute to the maturation of small 
intestinal ILF (47). In the same study, a more specific role in 
the early transition of CP into immature ILF was proposed for 
NOD1, which recognizes peptidoglycans (PGN) derived from 
Gram-negative bacteria. NOD1, which is expressed in small 
intestinal epithelial cells, induces upon recognition of PGN the 
secretion of factors, such as CCL20 or β-defensin 3 (mBD3). 
Both factors are ligands for CCR6, which is expressed by B cells 
and LTi cells. Thus, activation of NOD1 may regulate the 
formation of ILF by activating LTi cells and by supporting the 
CCR6-dependent recruitment of B cells to CP (48). Supporting 
this hypothesis, mice deficient either for CCR6 or mBD3 fail to 
develop ILF, and a similar phenotype could be observed in mice 
treated with a CCL20 neutralizing antibody (47).
LYMPHOiD ORGANS OF THe  
COLON – SiMiLARiTieS AND 
DiFFeReNCeS TO SMALL iNTeSTiNe
Interestingly, most of the factors and molecular mechanisms that 
govern the development of PP and SILT have been analyzed in the 
small intestine, while the formation of the respective lymphoid 
tissues in the colon has not been comprehensively studied until 
recently. Similar to the small intestine, also the colon of mice 
harbors distinct lymphoid tissues. Colonic patches represent 
the equivalents of PP in the small intestine. They are usually 
composed of two or more large B cell follicles with separate 
T cell areas and contain CD35+ FDCs as well as vessels with HEV. 
As in the small intestine, also SILT exists, which resemble in its 
appearance its small intestinal counterpart, ranging from small 
CP-like structures to mature colonic ILF containing one big B cell 
follicle with CD35+ FDC, but no defined T cell area (49, 50). 
As for PP, the development of colonic patches starts in utero with 
clustering of RORγt-expressing LTi cells and their interaction 
with VCAM-1+ stromal cells. Although the initial clustering of 
LTi cells at colonic patch primordium seems to be independent of 
LTα1β2–LTβR interaction, the further development into colonic 
patches strictly requires activation of this pathway as well as the 
sustained expression of CXCL13 (49). SILT development in the 
colon starts after birth with the clustering of LTi cells into CP-like 
structures surrounded by CD11c+ cells, and the successful for-
mation of these structures depends again on signaling via the 
LTβR pathway. Despite these important similarities, it is getting 
FiGURe 2 | Similarities and differences in the development of small intestinal and colonic lymphoid tissues. (A) Development of both PP and colonic 
patches starts before birth with the clustering of LTα1β2-expressing IL-7Rα+RORγt+ LTi cells together with LTo cells. LTi cell clustering and further development of 
both PP and colonic patches requires expression of CXCL13 and is dependent on LT-signaling. Whether the initial clustering of LTi cells in the colon depends on 
RET-expressing IL7Rα−CD11c+ cells, as it has been described for PP development, is not known. (B) ILF formation in both small intestine and colon starts after birth 
with the clustering of IL-7Rα+RORγt+ LTi cells in CP. Maintenance and further development of these structures into ILF requires LT signaling in both small intestine 
and the colon. In the small intestine, also signaling via the Ahr and the expression of CXCL13, RANKL and CCR6 is required, and the commensal microbiota induce 
ILF formation and maturation via activation of signaling pathways that include NOD1, NOD2, TLRs, and MyD88. In the colon, ILF formation does not seem to 
critically depend on CXCL13, RANKL, and CCR6. There, the presence of commensal microbiota rather inhibits ILF maturation, probably by inducing IL-25 
production from the epithelium, which in turn diminishes the secretion of IL-23, a cytokine that specifically promotes ILF maturation in the colon. Signals associated 
with intestinal inflammation or infection with enteric pathogens also induce ILF formation and maturation. Intestinal inflammation or infection may also result in the 
induction of TLO that form independently of LTi cells. TLO may be discriminated from ILF by structural differences such as the presence of T cell areas. A role for the 
intestinal nervous system for TLO induction in intestinal inflammation has been suggested.
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increasingly clear that also striking differences exist between the 
processes of lymphoid tissue formation in the small intestine and 
the colon (summarized in Figure 2). CXCL13 for example, while 
required for the formation of colonic patches and the recruitment 
of B cells into small intestinal CP, seems to be dispensable for 
colonic SILT formation, as numerous colonic ILF were observed in 
CXCL13-deficient mice (49). Likewise, ILF formation is blocked 
in the small intestine of mice deficient for RANKL, presumably 
due to a role for this cytokine in inducing CXCL13 expression 
in stromal cells. In contrast, ILF formation is not affected in the 
colon of RANKL-deficient mice (51). Furthermore, colonic ILF 
develop normally in CCR6-deficient mice, even though colonic 
LTi cells express CCR6, and expression of the ligand CCL20 was 
shown to be decreased in the colon of LTα-deficient mice, which 
fail to develop colonic lymphoid tissues (49). This indicates that in 
contrast to the small intestine, SILT formation in the colon is less 
dependent on the CCR6–CCL20 axis. Most striking, however, is 
the notion that microbiota-derived signals seem to be much less 
important for the formation of mature colonic ILF as compared to 
the small intestine. Two recent studies showed that in germ-free 
mice the formation of the whole spectrum of SILT in the colon 
is not significantly impaired (49, 50). Yet, MyD88 signaling was 
found to be necessary for full colonic ILF maturation, even in 
the absence of the microbiota (49). Whether MyD88 signaling is 
induced by activation of the IL-1R family, which also signal via 
the MyD88 adaptor, or the release of endogenous TLR ligands is, 
however, not clear so far. It should be mentioned in that respect, 
that in an earlier study a role for TLR2/4 was shown for colonic 
ILF maturation, however in a microbiota-dependent manner 
(47). Nevertheless, Donaldson and colleagues even found the 
numbers of colonic ILF increased in germ-free mice, which 
could be corrected in their study by transferring these mice to 
a conventional housing (50). Interestingly, intestinal coloniza-
tion of germ-free mice with microbiota was accompanied by 
upregulation of colonic IL-25 expression. IL-25 is produced upon 
microbial colonization by the intestinal epithelium, and it has 
been demonstrated that commensal microbiota-induced IL-25 
production dampens the activity of RORγt+ ILC and reduces 
TABLe 1 | Formation of lymphoid follicles in intestinal inflammation.
Species Phenotype Reference
Ahr−/−  
mice
Spontaneous lymphoid follicle formation 
in colon, anal prolapse, and increased 
intestinal inflammation upon infection
Fernandez-Salguero 
et al. (58) and Kiss 
et al. (43)
RORγt−/−  
mice
Spontaneous lymphoid follicle formation 
in colon, increased follicle numbers and 
enhanced pathology during DSS colitis. 
Blocking of lymphoid follicle formation 
reduced pathology
Lochner et al. (54)
TNFΔARE  
mice
Lymphoid follicle induction in terminal 
ileum during spontaneous ileitis
McNamee et al. (57)
WT mice Lymphoid follicle induction in the colon 
upon DSS colitis
Olivier et al. (66)
CD40L/B  
tg mice
Lymphoid follicle formation in small 
intestine and colon during spontaneous 
colitis
Kawamura et al. (65)
LN/PP- 
deficient  
mice
Formation of lymphoid follicles during 
DSS colitis, no correlation with disease 
severity
Spahn et al. (64)
Human De novo formation of lymphoid follicle 
in UC and CD
Kaiserling (62)
Human Description of lymphoid aggregates in 
UC lesions
Carlsen et al. (63)
Human Description of lymphoid aggregates in 
CD lesions
Makiyama et al. (59), 
Surawicz and Belic (60), 
and Fujimura et al. (61)
UC, ulcerative colitis; CD, Crohn’s disease.
6
Buettner and Lochner Secondary and Tertiary Lymphoid Tissues of the Intestine
Frontiers in Immunology | www.frontiersin.org September 2016 | Volume 7 | Article 342
IL-23 expression in the intestine (52, 53). Indeed, colonic ILF 
development was increased in IL-25-deficient mice (50). This 
was associated with enhanced expression of IL-23, suggesting 
that IL-25 may influence colonic ILF maturation by negatively 
regulating IL-23 production. The authors could confirm this 
hypothesis by showing that IL-23p19-deficient mice displayed a 
colon-specific decrease in ILF numbers, and identified colonic 
(but not small intestinal) CD11c+ cells within ILF as a source for 
IL-23 production. Thus, the commensal microbiota may still be 
important for regulating the status of the colonic SILT, however, 
by a process different from the small intestine, involving IL-23 
as an important (and colon-specific) factor for ILF development.
iLF iN iNTeSTiNAL iNFLAMMATiON
Despite the findings that ILF formation in the small intestine 
and the colon is initiated after birth and requires additional 
environmental factors, these structures may still be considered as 
SLO, since their development depends on the programed initial 
clustering of LTi cells into CP. In contrast, TLO can form as a 
consequence of an inflammatory process and are independent 
of the programed clustering of LTi cells. As the intestinal SILT 
already represents a flexible system of “inducible” SLO, the ques-
tion remains whether true TLO do also develop in this organ 
during inflammation. Evidence that TLO induction, indeed, 
occurs in the intestine comes from studies using RORγt-deficient 
mice, which lack all RORγt-dependent ILC and, therefore, all 
programed peripheral lymphoid tissues, including LN, PP, and 
colonic patches. In these mice, numerous ILF-like B cell follicles 
containing germinal centers develop spontaneously in the colon, 
demonstrating that formation of TLO is possible in the intestine 
in the absence of LTi cells (54). It is likely that the spontaneous for-
mation of such colonic TLO is compensating for the lack of other 
intestinal lymphoid tissues or critical components of the intestinal 
immune system (55). In fact, an increase in colonic ILF has also 
been observed in mice after the development of mLN, and PP 
was inhibited by the in utero blockage of LTβR and TNFRp55 or 
in mice that are deficient for the Ahr (43, 56). In RORγt-deficient 
mice, the development of colonic TLO was still dependent on 
LTβR signaling, and it was shown that B cells were the critical 
source of LTα1β2 in the absence of LTi cells (54). The induction 
of TLO in RORγt-deficient mice was strictly dependent on the 
microbiota and strongly enhanced upon induction of intestinal 
inflammation with dextran sodium sulfate (DSS). Interestingly, 
there was an intriguing correlation between the presence of TLO 
in the colon of RORγt-deficient mice and the severity of the 
colonic inflammation. The pathology could be reverted to levels 
seen in wild-type control mice by blocking the development of 
TLO using a LTβR–Ig fusion protein, suggesting that the TLO in 
this model indeed contribute to the severity of colitis. This finding 
complements data from other studies suggesting that increased 
formation of mucosal lymphoid tissues is associated with an exac-
erbation of intestinal pathology. In TNFΔARE mice, which serve 
as a TNFα-dependent model of Crohn’s Ileitis, induction of TLO 
within the chronically inflamed terminal ileum was observed (57). 
Aberrant production of CCL19 and CCL21 by these structures 
enhanced the density of infiltrating effector memory T cells and 
augmented their retention in the inflamed intestine, contribut-
ing to the perpetuation of ileitis. Also, the B cell follicles that 
develop in the colon of Ahr-deficient mice have been associated 
with intestinal pathology, such as the formation of anal prolapse, 
colonic hyperplasia, and increased inflammation upon intestinal 
infection (43, 58). There is ample evidence also from other stud-
ies in mice and in men that intestinal inflammation is associated 
with enhanced formation of structured lymphoid tissues (59–66) 
(summarized in Table 1). Yet, the contribution of these lymphoid 
organs to the perpetuation or exacerbation of the inflammatory 
pathology was, in the cases where it was tested, less evident.
Of note, the question whether the lymphoid organs that 
form in intestinal inflammatory diseases also represent de novo-
induced TLO instead of ILF that develop as SLO within the SILT 
network is, as of now, not completely clear. In this regard, the 
group of Reina Mebius recently reported the de novo forma-
tion of lymphoid tissues in the colon of mice treated with DSS 
(66). Although these structures showed all hallmarks of mature 
ILF in terms of the presence of B cell follicles, DC, FDC, and a 
vascular network, they also presented a distinct T cell area. It is 
likely that these lymphoid structures indeed represent de novo-
formed TLO, since they were not observed in non-treated control 
mice. Thus, despite the lack of a marker allowing to definitely 
discriminate ILF from TLO, it may be possible to distinguish 
inflammation-induced TLO from ILF by structural differences, 
such as the presence of defined T cell areas. Interestingly, the 
same study also suggested a specific role for the nervous system 
in colonic TLO formation. It was shown that disrupting the 
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innervation of the proximal colon by the vagus nerve prevented 
the induction of TLO upon DSS treatment, as a consequence of 
insufficient upregulation of CXCL13 and CCL20 expression by 
colonic stromal cells.
iLF iN iNTeSTiNAL iNFeCTiON
Under steady-state conditions, SILT functions mainly as a dynamic 
expandable system that contributes to the regulation of the intes-
tinal commensal microbiota by the induction of IgA [reviewed in 
Ref. (38)]. It has been shown that ILF, as well as other gut lymphoid 
organs, harbor in their interior populations of specific commensal 
bacteria, such as Alcaligenes spp., Achromobacter spp., and oth-
ers (67, 68). These lymphoid tissue-resident commensals could 
stimulate local ILC3 and T cell responses and induce the secretion 
of IL-10, which limited proinflammatory responses in the steady-
state and protected mice during DSS-induced colitis (69). Besides 
their role in establishing mutualism between the host and the 
commensal microbiota, ILF may, however, also participate in the 
immune response against specific intestinal pathogens. In that 
respect, it has been shown that in mice lacking LNs and PP, but 
not ILF, Salmonella typhimurium-specific IgA responses could be 
induced upon oral infection with this pathogen (70). Candidatus 
arthromicus [also known as segmented filamentous bacteria 
(SFB)] has been described as a bacterial strain with marked 
immunostimulatory properties, although it does not cause overt 
immunopathology (71). SFB colonizes mainly the terminal ileum 
of mice, where it can directly attach to the epithelium and induce 
the maturation of several intestinal immune functions, including 
IgA production and Th17 induction (72, 73). In mice containing 
a normal set of lymphoid organs, PP represent a major site for 
SFB-induced IgA production (74). However, when mice were 
made devoid of LN, PP, as well as CP-derived ILF by LTβR–Ig 
treatment, SFB induced the formation of small intestinal TLO 
capable of initiating an IgA response to SFB. Interestingly, IgA-
induction against a non-adherent and non-virulent strain of 
Escherichia coli occurred in PP, but was completely abolished in 
mice lacking PP. Overall, these data suggest that specific bacteria 
with immunostimulatory or pathogenic properties can stimulate 
the formation of ILF, which can substitute for PP as inductive sites 
for intestinal IgA. Interestingly, pathogen-induced formation of 
lymphoid follicles has also been observed in the mucosal tissue 
of the stomach. Although the stomach generally lacks organized 
or diffused lymphoid tissues, infection with Helicobacter pylori 
can induce the development of gastric lymphoid follicles in mice, 
presumably in an LTi cell-dependent manner (75). Of note, also 
intestinal parasites, such as the nematode Trichuris muris can 
induce the formation of ILFs in the colon of infected mice (76).
Evidence for a functional role of ILFs in host protection against 
intestinal infection comes from studies using the bacterium 
Citrobacter rodentium, a non-invasive Gram-negative mouse 
enteric pathogen that forms attaching and effacing (A/E) lesions 
in the intestinal epithelium, modeling the infection process of 
the human pathogens, enterohemorrhagic E. coli (EHEC) and 
enteropathogenic E. coli (EPEC) (77). During the early phase 
of infection, RORγt+ ILC3 produces large amounts of IL-22 
(78–80), which has a major protective role, e.g., by inducing 
the expression of antimicrobial proteins, such as RegIIIβ and 
RegIIIγ, by intestinal epithelial cells (81). Mice that lack ILC3 
are highly susceptible to intestinal infection with C. rodentium 
(78, 80), largely recapitulating the phenotype of IL-22-deficient 
mice (82). Importantly, the LTβR-pathway also plays an essential 
role for the defense against this pathogen, since LTβR-deficient 
mice were found to be highly susceptible to C. rodentium and 
to succumb rapidly upon infection (83, 84). It turned out that 
RORγt+ ILC were the critical cell type for the activation of LTβR-
signaling via their surface expression of LTα1β2 (84–86). It was 
furthermore demonstrated that the LT pathway was required 
for the subsequent induction of IL-22 production by ILC. 
Intriguingly, IL-22+ ILC closely interacted with DCs in colonic 
ILF, and it was shown that LTβR-expression by CD11c+ DC is a 
prerequisite for IL-22 induction in ILC (86). The data provided 
by the study of Tumanov and colleagues suggest that ILF, indeed, 
provide the necessary microenvironment for the close interac-
tion between RORγt+ ILC and DC. The LTα1β2–LTβR-mediated 
interaction results in IL-23 secretion by the DC, which in turn 
activates IL-22 production from the ILC. Importantly, both dis-
ruption of the LTβR pathway and IL-22 deficiency interfered with 
the induction of ILF and impaired their structural integrity (85). 
However, the surprising role of IL-22 for ILF formation was only 
observed after infection with C. rodentium, but not during the 
steady state. Together, these findings indicate that ILF not only 
provide the critical environment for the induction of an effective 
immune response toward intestinal infection but also demon-
strate an important role for RORγt+ ILC-derived IL-22 for the 
induction and maintenance of ILF under infectious conditions 
in the gut. Notably, a critical role of IL-22 has also been reported 
recently in a model of adenovirus-induced development of TLO 
in the salivary glands of mice (87). In the absence of IL-22, 
the recruitment of B cells into the developing TLO structures 
was significantly impaired, resulting in a strong reduction of 
autoantibody formation. It was shown that IL-22 production was 
necessary for the upregulation of CXCL12 and CXCL13 from 
epithelial and stromal cells within TLO, and therapeutic blocking 
of IL-22 inhibited the expression of both chemokines and the 
correct assembly of TLO. Although ILC were identified as IL-22 
producers, the majority of cells expressing this cytokine at the 
early phase were γδ T cells and αβ T cells at the later stage. These 
findings together, thus, suggest important regulatory role for 
IL-22 in the formation of lymphoid organs under inflammatory 
or infectious conditions at mucosal sites.
CONCLUDiNG ReMARKS
In contrast to most other lymphoid tissues of the body, the 
formation of ILF in the gut is initiated after birth and unfolds 
upon the reception of environmental signals associated with the 
uptake of food-derived compounds and microbial colonization. 
Despite these differences, ILF can be considered as SLO, since 
their development strictly requires the LTi-dependent formation 
of CP. This distinguishes ILF from TLO, which can be induced 
also in the absence of LTi cells and in response to an inflammatory 
trigger. Recent experiments in mice suggest that inflammation 
not only leads to an expansion of the existing SILT network 
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but also to the induction of TLO in the gut. Although it is not 
clear so far, to what extent TLO contribute to the inflammatory 
process and pathology in intestinal inflammation, disrupting 
TLO formation may represent a strategy for the treatment of 
chronic inflammatory disorders. Regarding its prominent role 
in lymphoid neogenesis, targeting the LTβR pathway may prove 
effective in blocking TLO development during inflammation. 
However, the human phase II studies that analyzed therapeutics 
targeting the lymphotoxin pathway showed only very limited 
effects in improving the symptoms of primary Sjögren’s syndrome 
or rheumatoid arthritis (88, 89). Another promising approach to 
interfere with TLO development is the blockade or neutralization 
of CXCL13 in order to prevent B cell recruitment into lymphoid 
structures. In this regard, antibody-mediated neutralization of 
CXCL13 in a mouse model for Sjögren’s syndrome resulted in 
improved disease phenotype and reduced lymphoid follicles in 
the submandibular glands (90). CXCL13 neutralization had also 
a beneficial effect in mouse models for rheumatoid arthritis and 
multiple sclerosis (91), although the effect on TLO formation 
was not determined in this study. Blocking CXCL13 in the 
NOD-mouse model for diabetes disrupted the organization of 
TLO in the pancreas of the mice, however, without affecting 
disease severity (92). These findings indicate that the effect of 
anti-CXCL13 treatment may be influenced by the specific char-
acteristics of the inflammatory model. In that respect, it will be 
interesting to see whether blocking of CXCL13 also impacts on 
gut inflammation and TLO development in the intestine.
Besides the well-known factors that are required for the devel-
opment of ILF, there are also cytokines like IL-22 entering the 
stage that may have a specific function in ILF biology. Also, IL-23, 
besides its established proinflammatory role within the TH17–
IL-23 axis (93), seems to influence ILF formation specifically in the 
colon, and has been associated with TLO formation in rheumatoid 
arthritis (94). Also, IL-17, which together with IL-22 is produced 
by neonatal RORγt+ LTi cells as well as by RORγt-expressing 
T cell subsets, has been implicated in TLO formation in the lung 
(95) and in a model of experimental allergic encephalomyelitis 
(96). Nevertheless, the significance of these cytokines for the 
development and structural maintenance of organized lymphoid 
tissues may strongly depend on the inflammatory context and 
the target organ. While, so far, no role for IL-17 in ILF formation 
has been reported, its requirement for TLO formation in the lung 
also depends strongly on the model used (97).
Increasing our knowledge on the similarities, but in par-
ticular also the differences, in the mechanisms that govern 
postnatal development of lymphoid tissues such as ILF in the 
small intestine and the colon may offer novel strategies for 
immunomodulation. It should also be taken into account that 
targeting cytokines, e.g. within the TH17–IL-23 axis, for the 
treatment of inflammatory disorders may in addition to the 
direct anti-inflammatory effects also critically influence the 
formation and function of lymphoid tissues.
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